Fortrea Holdings (FTRE) Accounts Payables (2022 - 2026)
Fortrea Holdings (FTRE) reported Accounts Payables of $70.8 million for Q1 2026, down 35.75% on a YoY basis from $110.2 million in Q1 2025, and up 138.38% quarter-over-quarter from $29.7 million in Q4 2025.
Fortrea Holdings (FTRE) Accounts Payables (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported Accounts Payables for 5 years, with the latest figure at $70.8 million in Q1 2026.
- For the quarter ending Q1 2026, Accounts Payables fell 35.75% year-over-year to $70.8 million; the trailing twelve-month figure through Mar 2026 stood at $70.8 million (down 35.75% YoY), and the FY2025 full-year result was $29.7 million, down 78.51% from the prior year.
- Accounts Payables for Q1 2026 stood at $70.8 million, up from $29.7 million in the prior quarter.
- The five-year high for Accounts Payables was $144.2 million in Q2 2024, with the low at $29.7 million in Q4 2025.
- Historically, Accounts Payables has averaged $104.0 million across 5 years, with a median of $110.2 million in 2025.
- Annual changes were most pronounced in 2023 — Accounts Payables jumped 63.07% — and 2025, when it sank 78.51%.
- Fortrea Holdings' Accounts Payables stood at $81.5 million in 2022, then jumped by 63.07% to $132.9 million in 2023, then rose by 3.99% to $138.2 million in 2024, then slumped by 78.51% to $29.7 million in 2025, then surged by 138.38% to $70.8 million in 2026.
- The last three Accounts Payables figures came in at $70.8 million (Q1 2026), $29.7 million (Q4 2025), and $49.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.05 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 83.00 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 8.64 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 489.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 34.55 Mn |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | 70.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70.80 Mn |
| Dec 31, 2025 | 29.70 Mn |
| Sep 30, 2025 | 49.50 Mn |
| Jun 30, 2025 | 92.60 Mn |
| Mar 31, 2025 | 110.20 Mn |
| Dec 31, 2024 | 138.20 Mn |
| Sep 30, 2024 | 137.60 Mn |
| Jun 30, 2024 | 144.20 Mn |
| Mar 31, 2024 | 131.30 Mn |
| Dec 31, 2023 | 132.90 Mn |
| Sep 30, 2023 | 128.30 Mn |
| Jun 30, 2023 | 105.30 Mn |
| Dec 31, 2022 | 81.50 Mn |